View Single Post
Old 05-02-2007, 11:43 PM   #12
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,783
additional comments

1)sorry I typed ASCO rather than SABCS(San Antonio meeting)

2) that study was different in that it was looking to restore tamoxifen efficacy in tumors that became tamoxifen resistant by developing her2 positivity where they did not have it before. That is very different from her2+ER+ TUMORS WHICH are by their nature relatively tamoxifen resistant from the get-go and which have a very different gene expression profile.

Enough for tonight!
Lani is offline   Reply With Quote